Valuation: Heron Therapeutics, Inc.

Market Cap 59.08M 53.71M 49.62M 44.81M 84.47M 5.55B 87.72M 596M 236M 2.98B 222M 217M 9.42B P/E 2026 *
-2.3x
P/E 2027 * -2.59x
Enterprise Value 59.08M 53.71M 49.62M 44.81M 84.47M 5.55B 87.72M 596M 236M 2.98B 222M 217M 9.42B EV / Sales 2026 *
0.42x
EV / Sales 2027 * 0.42x
Free-Float
98.94%
Yield 2026 *
-
Yield 2027 * -
1 day-8.44%
1 week-2.97%
Current month+2.38%
1 month-24.49%
3 months-15.56%
6 months-66.55%
Current year-78.13%
1 week 0.27
Extreme 0.268
0.41
1 month 0.27
Extreme 0.2662
0.42
Current year 0.26
Extreme 0.261
1.58
1 year 0.26
Extreme 0.261
1.58
3 years 0.26
Extreme 0.261
3.93
5 years 0.26
Extreme 0.261
11.2
10 years 0.26
Extreme 0.261
42.9
Manager TitleAgeSince
Chief Executive Officer 60 2023-04-02
Director of Finance/CFO 57 2023-06-15
Chief Operating Officer 43 2025-04-27
Director TitleAgeSince
Director/Board Member 64 2014-01-12
Director/Board Member 59 2016-06-21
Director/Board Member 51 2021-09-19
Date Insider Type Main position Quantity % Market Cap. Importance
10/31/26 Exercice

Executive/Senior Manager

26,717 0.0141%
10/31/26 Exercice

Chief Executive Officer

78,047 0.0411%
10/31/26 Exercice

Chief Financial Officer

26,717 0.0141%
Change 5-day change 1-year change 3-year change Capi.($)
-8.44%-2.97%-74.15%-66.94% 59.08M
-1.29%-1.76%+51.98%+64.66% 66.33B
-0.09%+7.58%+12.54%+93.05% 60.62B
+0.63%+1.03%+23.11%+90.78% 55.5B
-1.26%+1.06%+12.43%+109.27% 47.58B
-0.15%-2.61%+20.00%+28.62% 43.69B
-3.15%-13.22%+146.30%+681.96% 37.27B
+0.23%+1.66%+14.85%+49.06% 36.57B
+2.35%+0.06%+80.65%+59.68% 32.22B
+1.42%+7.41%-36.40%+393.49% 26.58B
Average -0.98%+0.89%+25.13%+150.36% 41B
Weighted average by Cap. -0.29%+0.33%+35.87%+150.10%

Financials

2026 *2027 *
Net sales 142M 129M 119M 107M 202M 13.3B 210M 1.43B 566M 7.13B 531M 520M 22.58B 140M 128M 118M 106M 201M 13.19B 208M 1.42B 561M 7.07B 527M 516M 22.39B
Net income -25.6M -23.28M -21.5M -19.42M -36.6M -2.4B -38.01M -258M -102M -1.29B -96.03M -94.03M -4.08B -25.9M -23.55M -21.75M -19.64M -37.03M -2.43B -38.46M -261M -104M -1.3B -97.16M -95.13M -4.13B
Net Debt - -
Projected Income Statement - Annual - Heron Therapeutics, Inc.
Logo Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutics that improve medical care. Its acute care product portfolio includes ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low-dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist indicated for postoperative nausea and vomiting in adults. CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is the first extended-release 5-HT3 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting associated with both MEC and anthracycline and cyclophosphamide combination chemotherapy regimens.
Employees
128
Date Price Change Volume
26-11-16 US$0.2843 -8.44% 5,895,317
26-11-13 US$0.3105 -4.73% 2,481,620
26-11-12 US$0.3259 -9.30% 7,204,586
26-11-11 US$0.3593 -3.96% 4,809,742
26-11-10 US$0.3741 +0.94% 11,114,810
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Heron Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
0.2843
Average target price
-
  1. Stock Market
  2. Stocks
  3. HRTX Stock